Warning: The NCBI web site requires JavaScript to function. more...
Cartilage degradation is fully reversible in the presence of aggrecanase but not matrix metalloproteinase activity.
Karsdal MA, Madsen SH, Christiansen C, Henriksen K, Fosang AJ, Sondergaard BC.
Arthritis Res Ther. 2008;10(3):R63. Epub 2008 May 30.
Related citations
Induction of increased cAMP levels in articular chondrocytes blocks matrix metalloproteinase-mediated cartilage degradation, but not aggrecanase-mediated cartilage degradation.
Karsdal MA, Sumer EU, Wulf H, Madsen SH, Christiansen C, Fosang AJ, Sondergaard BC.
Arthritis Rheum. 2007 May;56(5):1549-58.
Aggrecanase versus matrix metalloproteinases in the catabolism of the interglobular domain of aggrecan in vitro.
Little CB, Flannery CR, Hughes CE, Mort JS, Roughley PJ, Dent C, Caterson B.
Biochem J. 1999 Nov 15;344 Pt 1:61-8.
MAPKs are essential upstream signaling pathways in proteolytic cartilage degradation--divergence in pathways leading to aggrecanase and MMP-mediated articular cartilage degradation.
Sondergaard BC, Schultz N, Madsen SH, Bay-Jensen AC, Kassem M, Karsdal MA.
Osteoarthritis Cartilage. 2010 Mar;18(3):279-88. Epub 2009 Nov 11. Review.
Detection of aggrecanase- and MMP-generated catabolic neoepitopes in the rat iodoacetate model of cartilage degeneration.
Janusz MJ, Little CB, King LE, Hookfin EB, Brown KK, Heitmeyer SA, Caterson B, Poole AR, Taiwo YO.
Osteoarthritis Cartilage. 2004 Sep;12(9):720-8.
Relative contribution of matrix metalloprotease and cysteine protease activities to cytokine-stimulated articular cartilage degradation.
Sondergaard BC, Henriksen K, Wulf H, Oestergaard S, Schurigt U, Bräuer R, Danielsen I, Christiansen C, Qvist P, Karsdal MA.
Osteoarthritis Cartilage. 2006 Aug;14(8):738-48. Epub 2006 Mar 23.
Calcitonin directly attenuates collagen type II degradation by inhibition of matrix metalloproteinase expression and activity in articular chondrocytes.
Sondergaard BC, Wulf H, Henriksen K, Schaller S, Oestergaard S, Qvist P, Tankó LB, Bagger YZ, Christiansen C, Karsdal MA.
Osteoarthritis Cartilage. 2006 Aug;14(8):759-68. Epub 2006 Mar 20.
The 45 kDa collagen-binding fragment of fibronectin induces matrix metalloproteinase-13 synthesis by chondrocytes and aggrecan degradation by aggrecanases.
Stanton H, Ung L, Fosang AJ.
Biochem J. 2002 May 15;364(Pt 1):181-90.
Cyclosporin A inhibition of aggrecanase-mediated proteoglycan catabolism in articular cartilage.
Little CB, Hughes CE, Curtis CL, Jones SA, Caterson B, Flannery CR.
Arthritis Rheum. 2002 Jan;46(1):124-9.
Anabolic and catabolic function of chondrocyte ex vivo is reflected by the metabolic processing of type II collagen.
Olsen AK, Sondergaard BC, Byrjalsen I, Tanko LB, Christiansen C, Müller A, Hein GE, Karsdal MA, Qvist P.
Osteoarthritis Cartilage. 2007 Mar;15(3):335-42. Epub 2006 Oct 11.
Aggrecan degradation in human cartilage. Evidence for both matrix metalloproteinase and aggrecanase activity in normal, osteoarthritic, and rheumatoid joints.
Lark MW, Bayne EK, Flanagan J, Harper CF, Hoerrner LA, Hutchinson NI, Singer II, Donatelli SA, Weidner JR, Williams HR, Mumford RA, Lohmander LS.
J Clin Invest. 1997 Jul 1;100(1):93-106.
Turnover of type II collagen and aggrecan in cartilage matrix at the onset of inflammatory arthritis in humans: relationship to mediators of systemic and local inflammation.
Fraser A, Fearon U, Billinghurst RC, Ionescu M, Reece R, Barwick T, Emery P, Poole AR, Veale DJ.
Arthritis Rheum. 2003 Nov;48(11):3085-95.
Matrix turnover in human cartilage repair tissue in autologous chondrocyte implantation.
Roberts S, Hollander AP, Caterson B, Menage J, Richardson JB.
Arthritis Rheum. 2001 Nov;44(11):2586-98.
Peptides of type II collagen can induce the cleavage of type II collagen and aggrecan in articular cartilage.
Yasuda T, Tchetina E, Ohsawa K, Roughley PJ, Wu W, Mousa A, Ionescu M, Pidoux I, Poole AR.
Matrix Biol. 2006 Sep;25(7):419-29. Epub 2006 Jun 30.
Mechanisms involved in cartilage proteoglycan catabolism.
Caterson B, Flannery CR, Hughes CE, Little CB.
Matrix Biol. 2000 Aug;19(4):333-44. Review.
Matrix metalloproteinases and aggrecanases cleave aggrecan in different zones of normal cartilage but colocalize in the development of osteoarthritic lesions in STR/ort mice.
Chambers MG, Cox L, Chong L, Suri N, Cover P, Bayliss MT, Mason RM.
Arthritis Rheum. 2001 Jun;44(6):1455-65.
Comparison of the degradation of type II collagen and proteoglycan in nasal and articular cartilages induced by interleukin-1 and the selective inhibition of type II collagen cleavage by collagenase.
Billinghurst RC, Wu W, Ionescu M, Reiner A, Dahlberg L, Chen J, van Wart H, Poole AR.
Arthritis Rheum. 2000 Mar;43(3):664-72.
Kinetics of aggrecanase- and metalloproteinase-induced neoepitopes in various stages of cartilage destruction in murine arthritis.
van Meurs JB, van Lent PL, Holthuysen AE, Singer II, Bayne EK, van den Berg WB.
Arthritis Rheum. 1999 Jun;42(6):1128-39.
Degradation of type II collagen, but not proteoglycan, correlates with matrix metalloproteinase activity in cartilage explant cultures.
Kozaci LD, Buttle DJ, Hollander AP.
Arthritis Rheum. 1997 Jan;40(1):164-74.
Cartilage degradation independent of MMP/aggrecanases.
Sugimoto K, Iizawa T, Harada H, Yamada K, Katsumata M, Takahashi M.
Osteoarthritis Cartilage. 2004 Dec;12(12):1006-14.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on